--- title: "89BIO (NASDAQ:ETNB) Receives \"Overweight\" Rating from Cantor Fitzgerald" type: "News" locale: "en" url: "https://longbridge.com/en/news/263858362.md" description: "Cantor Fitzgerald has reiterated an \"overweight\" rating on 89BIO (NASDAQ:ETNB) shares. Other analysts have mixed views, with Weiss Ratings giving a \"sell (d-)\" rating, Wolfe Research downgrading to \"peer perform,\" and Zacks lowering to \"strong sell.\" The stock remains flat at $14.84, with a consensus rating of \"Hold\" and a target price of $25.81. 89BIO reported a quarterly EPS of ($0.71), missing estimates. The company focuses on therapies for liver and cardio-metabolic diseases, with a market cap of $2.20 billion." datetime: "2025-11-01T14:02:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263858362.md) - [en](https://longbridge.com/en/news/263858362.md) - [zh-HK](https://longbridge.com/zh-HK/news/263858362.md) --- # 89BIO (NASDAQ:ETNB) Receives "Overweight" Rating from Cantor Fitzgerald 89BIO (NASDAQ:ETNB - Get Free Report)'s stock had its "overweight" rating reissued by equities research analysts at Cantor Fitzgerald in a research note issued on Friday,Benzinga reports. A number of other research analysts have also commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of 89BIO in a research note on Wednesday, October 8th. Wolfe Research lowered shares of 89BIO from an "outperform" rating to a "peer perform" rating in a research note on Friday, September 19th. Zacks Research lowered shares of 89BIO from a "hold" rating to a "strong sell" rating in a research note on Monday, October 20th. HC Wainwright lowered shares of 89BIO from a "buy" rating to a "neutral" rating and set a $14.50 price objective on the stock. in a research note on Friday, September 19th. Finally, Raymond James Financial lowered shares of 89BIO from a "strong-buy" rating to a "market perform" rating in a research note on Friday, September 19th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, 89BIO has a consensus rating of "Hold" and a consensus target price of $25.81. **Check Out Our Latest Report on 89BIO** ## 89BIO Stock Performance Shares of NASDAQ:ETNB remained flat at $14.84 during trading hours on Friday. 55,645,300 shares of the company's stock traded hands, compared to its average volume of 6,202,408. The firm has a fifty day moving average price of $12.52 and a two-hundred day moving average price of $10.30. 89BIO has a 12 month low of $4.16 and a 12 month high of $15.06. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of -4.11 and a beta of 1.27. The company has a debt-to-equity ratio of 0.07, a current ratio of 15.19 and a quick ratio of 15.19. 89BIO (NASDAQ:ETNB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.22). During the same period last year, the company earned ($0.48) earnings per share. As a group, research analysts anticipate that 89BIO will post -3.19 EPS for the current year. ## Institutional Investors Weigh In On 89BIO Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its stake in shares of 89BIO by 9,265.1% in the 1st quarter. CWM LLC now owns 5,900 shares of the company's stock valued at $43,000 after purchasing an additional 5,837 shares during the last quarter. KBC Group NV acquired a new stake in shares of 89BIO in the 2nd quarter valued at $55,000. Osaic Holdings Inc. lifted its stake in shares of 89BIO by 25.9% in the 2nd quarter. Osaic Holdings Inc. now owns 6,463 shares of the company's stock valued at $63,000 after purchasing an additional 1,330 shares during the last quarter. AlphaQuest LLC lifted its stake in shares of 89BIO by 213.8% in the 2nd quarter. AlphaQuest LLC now owns 6,614 shares of the company's stock valued at $65,000 after purchasing an additional 4,506 shares during the last quarter. Finally, Ieq Capital LLC acquired a new stake in shares of 89BIO in the 1st quarter valued at $89,000. ## 89BIO Company Profile (Get Free Report) 89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. ## Further Reading - Five stocks we like better than 89BIO - What is a Dividend King? - Cameco's $80 Billion U.S. Nuclear Deal Changes Everything - Stock Trading Terms - Stock Terms Every Investor Needs to Know - NU Stock: U.S. Bank License May Be the Next Growth Catalyst - 3 Small Caps With Big Return Potential - 5 Stocks to Stuff Your Portfolio This November _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in 89BIO Right Now? Before you consider 89BIO, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 89BIO wasn't on the list. While 89BIO currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ETNB.US](https://longbridge.com/en/quote/ETNB.US.md)